Revenue → Gross profit: $15.6BPharmaceutical → Revenue: $14.5BMedical devices → Revenue: $8.0BRevenue → Cost of revenue: $6.9BGross profit → SG&A: $5.7BGross profit → Operating profit: $5.6BOncology → Pharmaceutical: $5.1BImmunology → Pharmaceutical: $4.7BOperating profit → Net profit: $4.7BGross profit → R&D: $3.4BSurgery → Medical devices: $2.5BOrthopaedics → Medical devices: $2.3BInterventional → Medical devices: $1.9BNeuroscience → Pharmaceutical: $1.8BVision → Medical devices: $1.3BOperating profit → Tax: $1.1BPulmonary → Pharmaceutical: $1.0BInfectious diseases → Pharmaceutical: $1.0BOther pharma → Pharmaceutical: $0.9BGross profit → Other expense: $0.7BGross profit → In process reseach: $0.2BInterest → Operating profit: $0.1BRestructuring → Operating profit: $0.0BImmunology: $4.7BPharmaceutical: $14.5BInfectious diseases: $1.0BNeuroscience: $1.8BOncology: $5.1BPulmonary: $1.0BOther pharma: $0.9BRevenue: $22.4BMedical devices: $8.0BInterventional: $1.9BOrthopaedics: $2.3BSurgery: $2.5BVision: $1.3BGross profit: $15.6BCost of revenue: $6.9BOperating profit: $5.7BSG&A: $5.7BR&D: $3.4BOther expense: $0.7BIn process reseach: $0.2BNet profit: $4.7BInterest: $0.1BRestructuring: $0.0BTax: $1.1Bcreated with SankeyArt.comImmunology$4.7B5% Y/YPharmaceutical$14.5B6% Y/YInfectious diseases$1.0BNeuroscience$1.8BOncology$5.1BPulmonary$1.0BOther pharma$0.9BRevenue$22.4B-12% Y/YMedical devices$8.0B2% Y/YInterventional$1.9BOrthopaedics$2.3BSurgery$2.5BVision$1.3BGross profit$15.6B-10% Y/YCost of revenue$6.9B-16% Y/YOperating profit$5.7B-9% Y/YSG&A$5.7B-15% Y/YR&D$3.4B-10% Y/YOther expense$0.7BIn process reseach$0.2BNet profit$4.7B-9% Y/YInterest$0.1B443% Y/YRestructuring$13MTax$1.1B14% Y/YJohnson & Johnson Q2 FY24 Income Statement
2022
Q4 Full Year
2023
Q1 Q2 Q3 Q4 Full Year
2024
Q1 Q2 Q3